---
title: "Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300009.SZ.md"
symbol: "300009.SZ"
name: "Anhui Anke Biotechnology (Group) Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-21T22:32:13.587Z"
locales:
  - [en](https://longbridge.com/en/quote/300009.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300009.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300009.SZ.md)
---

# Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ)

## Company Overview

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, immunohistochemical, sperm DNA fragmentation staining, leptin, and immunohistochemical diagnostic kits.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.ankebio.com](https://www.ankebio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: B (0.34)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 11 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.02% |  |
| Net Profit YoY | -0.63% |  |
| P/B Ratio | 2.93 |  |
| Dividend Ratio | 1.80% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 13856833204.30 |  |
| Revenue | 2554560790.43 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 15.72% | A |
| Profit Margin | 27.11% | A |
| Gross Margin | 75.59% | A |
| Revenue YoY | 2.02% | C |
| Net Profit YoY | -0.63% | C |
| Total Assets YoY | 10.98% | B |
| Net Assets YoY | 15.11% | B |
| Cash Flow Margin | 116.58% | C |
| OCF YoY | 2.02% | C |
| Turnover | 0.48 | C |
| Gearing Ratio | 13.42% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Anhui Anke Biotechnology (Group) Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.02%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-0.63%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.93",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.80%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "13856833204.30",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2554560790.43",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "15.72%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "27.11%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "75.59%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "2.02%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-0.63%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "10.98%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "15.11%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "116.58%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "2.02%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.48",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "13.42%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 19.89 | 3/81 | 26.31 | 24.52 | 21.64 |
| PB | 2.91 | 45/81 | 4.32 | 3.94 | 3.60 |
| PS (TTM) | 5.39 | 23/81 | 6.84 | 6.37 | 5.97 |
| Dividend Yield | 1.81% | 17/81 | 2.59% | 2.33% | 1.55% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | Biocytogen (688796.SH) | A | A | E | B | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-06T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.26 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300009.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300009.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300009.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300009.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**